Clinical trials
Gastrointestinal Stromal Tumor (GIST) clinical trials
Below are recruiting gastrointestinal stromal tumor (gist) clinical trials, each written for real people, not researchers. We’re tracking 42 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07585266RecruitingPhase 3
New drug velzatinib versus imatinib for untreated GIST
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
Omaha, NebraskaAges 18 years+ - NCT07406633RecruitingPhase 2
KQB198 plus imatinib for advanced GIST
This trial tests a new drug called KQB198 combined with imatinib for people with advanced or metastatic gastrointestinal stromal tumor (GIST) that has a specific KIT or PDGFRA mutation. The goal is to see if this combination works better than imatinib alone as a first treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT07411118Recruiting
Comparing two ways to remove stomach GIST tumors with an endoscope
This trial compares two endoscopic techniques (EFTR and STER) for removing small to medium-sized GIST tumors from the stomach wall. It aims to see which method is safer and more effective.
ShanghaiAges 18–75 - NCT03594422RecruitingPhase 1
Testing an oral drug for GIST or other solid tumors
This Phase 1 trial tests HQP1351, a new oral cancer drug, in people with advanced GIST or other solid tumors that have not responded to prior treatment. It’s mainly designed to check safety and how the drug works in the body, which may lead to better options for tumors that have progressed.
Guangzhou, GuangdongAges 12 years+ - NCT03602092Recruiting
GIST patient registry to improve real-world care
This observational study keeps a registry of people diagnosed with gastrointestinal stromal tumor (GIST) to collect real-life information over time. It may help doctors better understand outcomes and care patterns for future patients.
TaipeiAges 20 years+ - NCT03716089Recruiting
Laparoscopic surgery for stomach GIST by tumor site
This trial studies whether doing laparoscopic surgery for stomach GISTs (gastrointestinal stromal tumors) works and is safe when the tumor is in a “favorable” versus “unfavorable” location. You might be eligible if your tumor is confirmed as GIST and doctors expect to remove it completely using keyhole surgery.
Fuzhou, FujianAges 18–75 - NCT04557969Recruiting
Surgery and tumor testing in gastrointestinal stromal tumors (GIST)
This study looks at how surgery for gastrointestinal stromal tumors (GIST) works, and collects tumor samples to study them under the microscope and by DNA testing. Your results may help researchers better predict tumor behavior and guide future treatment.
Bethesda, MarylandAges 6 years+ - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Los Angeles, CaliforniaAges 12 years+ - NCT04933669RecruitingPhase 2
Pre-surgery imatinib for high-risk stomach or gut GIST
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
Hangzhou, ZhejiangAges 18–80 - NCT07697248Recruiting
GIST patient registry study
This study is creating a registry to track people with GIST over time. Participating helps researchers learn more about the disease and improve future care.
Wayne, New JerseyAges Any age - NCT05009927RecruitingPhase 2
Check whether continuing imatinib works after long GIST control
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
BesançonAges 18 years+ - NCT05152472RecruitingPhase 2
Imatinib plus atezolizumab versus imatinib alone for advanced GIST
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
Lyon, RhôneAges 18 years+ - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Birmingham, AlabamaAges 18 years+ - NCT05366816RecruitingPhase 2
Blood test–guided sunitinib or regorafenib for GIST
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
Miami, FloridaAges 18 years+ - NCT05385549RecruitingPhase 2
5-Year imatinib after GIST surgery for high-risk patients
This study looks at taking imatinib (a targeted anti-cancer pill) for 5 years after your GIST tumor has been fully removed. It is meant to lower the chance that GIST comes back in people considered “high risk.”
Seoul, SeoulAges 20 years+ - NCT05408897Recruiting
Blood test to predict risk after surgery for high-risk GIST
This study uses a “liquid biopsy” blood test to look for leftover cancer signals after surgery. It aims to predict how well treatment will work and how likely the cancer is to come back in people with high-risk GIST.
Beijing, Beijing MunicipalityAges Any age - NCT05461664Recruiting
Avapritinib for advanced GIST without PDGFRA exon 18 changes
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
GuangzhouAges 18 years+ - NCT05493215RecruitingPhase 2
Imatinib drug-monitoring for GIST with specific gene changes
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
Lexington, KentuckyAges 18 years+ - NCT05500391RecruitingPhase 2
Testing whether remote nurse monitoring works like in-person checks
This Phase 2 study compares two ways of checking your cancer follow-up: a doctor or nurse visits in person versus remote monitoring by phone and imaging. The goal is to see whether remote monitoring can safely replace or match in-person care for certain low-risk cancers and after surgery.
AmiensAges 18 years+ - NCT05661643RecruitingPhase 2
Temozolomide for GIST tumors with SDH deficiency
This trial tests how well temozolomide works and how safe it is for people with GIST (a type of stomach/intestine tumor) that is SDH-deficient and has no KIT or PDGFRα mutations. It may help by targeting tumor DNA repair weakness seen in this SDH-deficient subtype.
Seoul, SeoulAges 20 years+ - NCT05751733Recruiting
Apatinib versus standard drug for advanced GIST after imatinib
This trial studies whether apatinib works better than the usual second-line targeted tablet for advanced gastrointestinal stromal tumor (GIST) after imatinib (or avatinib) no longer works. It may help people whose cancer has grown despite treatment or who couldn’t tolerate it.
Changsha, HunanAges 18 years+ - NCT05905887RecruitingPhase 2
Rivoceranib and paclitaxel for advanced gastrointestinal stromal tumor
This Phase 2 trial tests whether combining rivoceranib with paclitaxel can shrink or control advanced metastatic gastrointestinal stromal tumor (GIST) after standard medicines have stopped working. It may help people whose GIST has progressed despite prior treatments like imatinib, sunitinib, and regorafenib.
Seoul, SeoulAges 20 years+ - NCT05938309Recruiting
Safety study of laparoscopic surgery for large stomach GISTs
This study looks at how safe laparoscopic surgery is for stomach GISTs that are 5 cm or larger. If you’re eligible and choose to participate, your team will plan and perform surgery and track safety outcomes.
Fuzhou, FujianAges 18–75 - NCT06326346RecruitingPhase 2
Oral paclitaxel for advanced GIST after other treatments fail
This trial tests an oral form of paclitaxel (a chemotherapy drug) for people with advanced gastrointestinal stromal tumor (GIST) that has stopped responding to or caused side effects with imatinib, sunitinib, and regorafenib. It aims to see if this treatment can help when other options have run out.
Seoul, SongpaguAges 20 years+
Hear when a new Gastrointestinal Stromal Tumor (GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Gastrointestinal Stromal Tumor (GIST) trials by city
Studies with a site in or near these metro areas.
Gastrointestinal Stromal Tumor (GIST) trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for gastrointestinal stromal tumor (gist)?
- Yes. Clin2 currently lists 42 recruiting gastrointestinal stromal tumor (gist) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastrointestinal stromal tumor (gist) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastrointestinal stromal tumor (gist) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.